Skip to content

Volume 86 · 560

Public Law 92–387

To amend the Federal Food, Drug, and Cosmetic Act to provide for a current listing of each drug manufactured, prepared, propagated, compounded, or processed by a registrant under that Act, and for other purposes.

Approved August 16, 1972

Statutory text

AN ACT

To amend the Federal Food, Drug, and Cosmetic Act to provide for a current listing of each drug manufactured, prepared, propagated, compounded, or processed by a registrant under that Act, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

Section 1.

This Act may be cited as the “Drug Listing Act of 1972”.

Sec. 2.

The Federal Government which is responsible for regulating drugs has no ready means of determining what drugs are actually being manufactured or packed by establishments registered under the Federal

52 Stat. 1040.

21 USC 301.

Food, Drug, and Cosmetic Act except by periodic inspection of such registered establishments. Knowledge of which particular drugs are being manufactured or packed by each registered establishment would substantially assist in the enforcement or Federal laws requiring that such drugs be pure, safe, effective, and properly labeled. Information on the discontinuance of a particular drug could serve to alleviate the burden of reviewing and implementing enforcement actions against drugs which, although commercially discontinued, remain active for regulatory purposes. Information on the type and number of different drugs being manufactured or packed by drug establishments could permit more effective and timely regulation by the agencies of the Federal Government responsible for regulating drugs, including identification of which drugs in interstate commerce are subject to section 505 or 507, or to other provisions of the Federal

76 Stat. 781.

59 Stat. 463.

21 USC 355, 357.

Registration, drug list require merits.

76 Stat. 794.

Food, Drug, and Cosmetic Act.

Sec. 3.

Section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360) is amended by adding at the end of the following new subsection:

“(j)
(1)

Every person who registers with the Secretary’ under subsection (o), (c), or (d) shall, at the time of registration under any such subsection, file with the Secretary a list of all drugs (by established

52 Stat. 1050; 76 Stat. 790.

21 USC 352.

name (as defined in section 502(e)) and by any proprietary name) which are being manufactured, prepared, propagated, compounded, or processed by him for commercial distribution and which he has not included in any list of drugs filed by him with the Secretary under this paragraph or paragraph (2) before such time of registration. Such list shall be prepared in such form and manner as the Secretary may prescribe and shall be accompanied by—

“(A)

in the case of a drug contained in such list and subject to

55 Stat. 851.

82 Stat. 343.

21 USC 356, 360b.

65 Stat. 648.

21 USC 353.

section 505, 506, 507, or 512, a reference to the authority for the marketing of such drug and a copy of all labeling for such drug;

“(B)

in the case of any other drug contained in such list—

“(i)

which is subject to section 503(b) (1), a copy of all labeling for such drug, a representative sampling of advertisements for such drug, and, upon request made by the Secretary for good cause, a copy of all advertisements for a particular drug product, or

“(ii)

which is not subject to section 503(b)(1), the label and package insert for such drug and a representative sampling of any other labeling for such drug;

“(C)

in the case of any drug contained in such list which is described in subpararaph (B), a quantitative listing of its active ingredient or ingredients, except that with respect to a particular drug product the Secretary may require, the submission of a quantitative listing of all ingredients if he finds that such submission is necessary to carry out the purposes of this Act; and

“(D)

if the registrant filing the list has determined that a particular drug product contained in such list is not subject to section 505, 506, 507, or 512, a brief statement of the basis upon which the registrant made such determination if the Secretary requests such a statement with respect to that particular drug product.

“(2)

Each person who registers with the Secretary under this section

Reports.

shall report to the Secretary once during the month of June of each year and once during the month of December of each year the following information:

“(A)

A list of each drug introduced by the registrant for commercial distribution which has not been included in any list previously filed by him with the Secretary under this subparagraph or paragraph (1) of this subsection. A list under this subparagraph shall list a drug by its established name (as defined in section 502(e)) and by any proprietary name it may have and shall

52 Stat. 1050; 76 Stat. 790.

21 USC 352.

be accompanied by the other information required by paragraph (1).

“(B)

If since the date the registrant last made a report under this paragraph (or if he has not made a report under this paragraph, since the effective date of this subsection) he has discontinued the manufacture, preparation, propagation, compounding, or processing for commercial distribution of a drug included in a list filed by him under subparagraph (A) or paragraph (1); notice of such discontinuance, the date of such discontinuance, and the identity (by established name (as defined in section 502 (e)) and by any proprietary name) of such drug.

“(C)

It since the date the registrant reported pursuant to subparagraph (B) a notice of discontinuance he has resumed the manufacture, preparation, propagation, compounding, or processing for commercial distribution of the drug with respect to which such notice of discontinuance was reported; notice of such resumption, the date of such resumption, the identity of such drug (by established name (as defined in section 502(e)) and by any proprietary name), and the other information required by paragraph (1), unless the registrant has previously reported such resumption to the Secretary pursuant to this subparagraph.

“(D)

Any material change in any information previously submitted pursuant to this paragraph or paragraph (1).

“(3)

The Secretary may also require each registrant under this section

Drug product list.

to submit a list of each drug product which (A) the registrant is manufacturing, preparing, propagating, compounding, or processing for commercial distribution, and (B) contains a particular ingredient. The Secretary may not require the submission of such a list unless he has made a finding that the submission of such a Est is necessary to carry out the purposes of this Act.”

Sec. 4.

(a)

Section 510(e) of such Act is amended by adding at the

76 Stat. 794.

21 USC 360.

end thereof the following: “The Secretary may also assign a listing number to each drug or class of drugs listed under subsection (j). Any

Ante, p. 560.

number assigned pursuant to the preceding sentence shall be the same as that assigned pursuant to the National Drug Code.”.

(b)

Section 510(f) of such Act is amended by inserting before the period the following: “; except that any fist submitted pursuant to paragraph (3) of subsection (j) and the information accompanying any fist or notice filed under paragraph (1) or (2) of that subsection shall be exempt from such inspection unless the Secretary finds that such an exemption would be inconsistent with protection of the public health”.

(c)

The second sentence of section 510(i) of such Act is amended by inserting “shall require such establishment to provide the information

Ante, p. 560.

required by subsection (j) and” immediately before “shall include”.

(d)

Clause (1) of the second sentence of section 505(e) of such

76 Stat. 781.

Act (21 U.S.C. 355(e)) is amended by inserting “or to comply with the notice requirements of section 510 (j) (2)” immediately after “subsection (j)”.

(e)

Section 301 (p) of such Act (21’U.S.C. 331 (p)) is amended to read as follows:

“(p)

The failure to register in accordance with section 510, the failure to provide any information required by section 510(j), or the fa i lure to provide a notice required by section 510 (j) (2).”

Sec. 5.

The amendments made by this Act shall take effect on the first day of the sixth month beginning after the date of enactment of this Act.

Approved August 16, 1972.

Parsed from the official Statutes at Large USLM XML in 86.xml